Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE: Spironolactone for Blood Pressure Control in Stroke Survivors
NCT04760717Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone in hypertension (HTN), sponsored by Yale University. Started Mar 2021; status: active, not recruiting.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04760717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760717.